866-997-4948(US-Canada Toll Free)

Paraganglioma (Glomus Jugulare Tumor) Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Oncology

No. of Pages : 34 Pages


Global Markets Directs, \'Paraganglioma (Glomus Jugulare Tumor) Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Paraganglioma (Glomus Jugulare Tumor), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Paraganglioma (Glomus Jugulare Tumor). 

Paraganglioma (Glomus Jugulare Tumor) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Paraganglioma (Glomus Jugulare Tumor).
  • A review of the Paraganglioma (Glomus Jugulare Tumor) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Paraganglioma (Glomus Jugulare Tumor) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Paraganglioma (Glomus Jugulare Tumor).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Paraganglioma (Glomus Jugulare Tumor) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Paraganglioma (Glomus Jugulare Tumor) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Paraganglioma (Glomus Jugulare Tumor) 7
Paraganglioma (Glomus Jugulare Tumor) Therapeutics under Development by Companies 9
Paraganglioma (Glomus Jugulare Tumor) Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Paraganglioma (Glomus Jugulare Tumor) Therapeutics Products under Development by Companies 14
Paraganglioma (Glomus Jugulare Tumor) Therapeutics Products under Investigation by Universities/Institutes 15
Companies Involved in Paraganglioma (Glomus Jugulare Tumor) Therapeutics Development 16
Molecular Insight Pharmaceuticals, Inc. 16
Paraganglioma (Glomus Jugulare Tumor) Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
iobenguane I 131 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
pazopanib hydrochloride - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
sunitinib malate - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
everolimus - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Temsirolimus + Vinorelbine Ditartrate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Temozolomide + Vorinostat - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Dovitinib - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Paraganglioma (Glomus Jugulare Tumor) Therapeutics Drug Profile Updates 32

Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Table


Number of Products Under Development for Paraganglioma (Glomus Jugulare Tumor), H2 2012 7
Products under Development for Paraganglioma (Glomus Jugulare Tumor) Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Molecular Insight Pharmaceuticals, Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Paraganglioma (Glomus Jugulare Tumor) Therapeutics Drug Profile Updates 32

List of Chart


Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor), H2 2012 7
Products under Development for Paraganglioma (Glomus Jugulare Tumor) Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *